Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

HIV transmission.

Shaw GM, Hunter E.

Cold Spring Harb Perspect Med. 2012 Nov 1;2(11). pii: a006965. doi: 10.1101/cshperspect.a006965. Review.

2.

HIV prevention trial in women is abandoned after drugs show no impact on infection rates.

Roehr B.

BMJ. 2011 Apr 20;342:d2613. doi: 10.1136/bmj.d2613. No abstract available.

PMID:
21508055
3.

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, Spacek MB, Heidt PE, Cohen MS, Kashuba AD.

J Infect Dis. 2011 May 15;203(10):1484-90. doi: 10.1093/infdis/jir059.

4.

Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice.

Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):8-13.

5.

Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8.

6.

Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.

Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R.

PLoS One. 2010 Dec 21;5(12):e15257. doi: 10.1371/journal.pone.0015257.

7.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team.

N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.

8.

Pharmacologic opportunities for HIV prevention.

Nicol MR, Kashuba AD.

Clin Pharmacol Ther. 2010 Nov;88(5):598-609. doi: 10.1038/clpt.2010.189. Epub 2010 Sep 29. Review. Erratum in: Clin Pharmacol Ther. 2011 Aug;90(2):343.

9.

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

Supervie V, García-Lerma JG, Heneine W, Blower S.

Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12381-6. doi: 10.1073/pnas.1006061107. Epub 2010 Jun 28.

10.

Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.

García-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, Pau CP, Barr JR, Hanson DL, Otten R, Paxton L, Folks TM, Heneine W.

Sci Transl Med. 2010 Jan 13;2(14):14ra4. doi: 10.1126/scitranslmed.3000391.

11.

Genetic and antigenic features of the transmitted virus.

Keele BF, Derdeyn CA.

Curr Opin HIV AIDS. 2009 Sep;4(5):352-7. doi: 10.1097/COH.0b013e32832d9fef. Review.

PMID:
20048697
12.

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.

Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, Tressler R, Worsley J, Kashuba AD.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):546-53. doi: 10.1097/QAI.0b013e3181ae69c5.

13.

Glycerol monolaurate prevents mucosal SIV transmission.

Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT.

Nature. 2009 Apr 23;458(7241):1034-8. doi: 10.1038/nature07831. Epub 2009 Mar 4.

14.

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR 3rd, Sloan CE, Sax PE, Walensky RP.

Clin Infect Dis. 2009 Mar 15;48(6):806-15. doi: 10.1086/597095.

15.

Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.

Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD.

AIDS. 2008 Sep 12;22(14):1829-39. doi: 10.1097/QAD.0b013e32830e00f5.

PMID:
18753932
16.

Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward.

Padian NS, Buvé A, Balkus J, Serwadda D, Cates W Jr.

Lancet. 2008 Aug 16;372(9638):585-99. doi: 10.1016/S0140-6736(08)60885-5. Epub 2008 Aug 5. Review.

PMID:
18687456
17.

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. doi: 10.1073/pnas.0802203105. Epub 2008 May 19.

18.

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W.

PLoS Med. 2008 Feb;5(2):e28. doi: 10.1371/journal.pmed.0050028.

19.

Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.

Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV.

PLoS Med. 2008 Jan 15;5(1):e16. doi: 10.1371/journal.pmed.0050016.

20.
Items per page

Supplemental Content

Write to the Help Desk